Abstract：
UNASSIGNED: This study assesses the efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders (NMOSD).
UNASSIGNED: The study initially included 40 patients with NMOSD diagnosed, after excluding patients who did not meet the complete inclusion criteria. Patients in the conventional group received routine clinical treatment, while patients in the study group received additional treatment with rituximab on the basis of the conventional treatment. Baseline data and clinically relevant indicators were collected for all patients, and the efficacy was compared between the two groups.
UNASSIGNED: Baseline data were comparable between the two groups (p > 0.05). The EDSS scores after clinical treatment in the study group were lower than those in the conventional group, and the difference in EDSS scores before and after treatment was higher than that in the conventional group (p < 0.05). The difference in visual acuity correction before and after treatment was not significant between the two groups (p > 0.05). Laboratory indicators in the study group after clinical treatment were superior to those in the conventional group (all p < 0.05). The recurrence rate after clinical treatment in the study group was significantly lower than that in the conventional group (p < 0.05). Adverse reactions after clinical treatment in the study group were less than those in the conventional group (p < 0.05).
UNASSIGNED: This study found that rituximab demonstrated significant efficacy in the acute attacks and recurrence prevention of NMOSD, emphasizing its relatively good safety and tolerability. It highlights the potential of rituximab in treating NMOSD and provides valuable insights for future disease management.
UNASSIGNED: The study initially included 40 patients with NMOSD diagnosed, after excluding patients who did not meet the complete inclusion criteria. Patients in the conventional group received routine clinical treatment, while patients in the study group received additional treatment with rituximab on the basis of the conventional treatment. Baseline data and clinically relevant indicators were collected for all patients, and the efficacy was compared between the two groups.
UNASSIGNED: Baseline data were comparable between the two groups (p > 0.05). The EDSS scores after clinical treatment in the study group were lower than those in the conventional group, and the difference in EDSS scores before and after treatment was higher than that in the conventional group (p < 0.05). The difference in visual acuity correction before and after treatment was not significant between the two groups (p > 0.05). Laboratory indicators in the study group after clinical treatment were superior to those in the conventional group (all p < 0.05). The recurrence rate after clinical treatment in the study group was significantly lower than that in the conventional group (p < 0.05). Adverse reactions after clinical treatment in the study group were less than those in the conventional group (p < 0.05).
UNASSIGNED: This study found that rituximab demonstrated significant efficacy in the acute attacks and recurrence prevention of NMOSD, emphasizing its relatively good safety and tolerability. It highlights the potential of rituximab in treating NMOSD and provides valuable insights for future disease management.
摘要：
目的：本研究评估利妥昔单抗治疗视神经脊髓炎谱系障碍（NMOSD）的疗效。方法：该研究最初包括40例诊断为NMOSD的患者，排除不符合完全纳入标准的患者后.常规组患者接受常规临床治疗,而研究组患者在常规治疗的基础上加用利妥昔单抗治疗。收集所有患者的基线数据和临床相关指标，比较两组疗效。结果:两组基线资料具有可比性(P>0.05)。研究组临床治疗后EDSS评分低于常规组,治疗前后EDSS评分差异高于常规组(P<0.05)。两组治疗前后视力矫正率差异无统计学意义(P>0.05)。研究组临床治疗后各项实验室指标均优于常规组(均P<0.05)。研究组临床治疗后复发率明显低于常规组(P<0.05)。研究组临床治疗后的不良反应少于常规组(P<0.05)。结论：本研究发现利妥昔单抗在预防NMOSD急性发作和复发方面具有显著疗效。强调其相对较好的安全性和耐受性。它强调了利妥昔单抗治疗NMOSD的潜力，并为未来的疾病管理提供了有价值的见解。
